BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hwang JP, LoConte NK, Rice JP, Foxhall LE, Sturgis EM, Merrill JK, Torres HA, Bailey HH. Oncologic Implications of Chronic Hepatitis C Virus Infection. J Oncol Pract 2019;15:629-37. [PMID: 31825756 DOI: 10.1200/JOP.19.00370] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Yang X, Tang Y, Xu D, Zhang G, Xu P, Tang H, Pang L. Efficacy and safety of ledipasvir/sofosbuvir for hepatitis C among drug users: a systematic review and meta-analysis. Virol J 2021;18:156. [PMID: 34315488 DOI: 10.1186/s12985-021-01625-w] [Reference Citation Analysis]
2 Ziogas DC, Kostantinou F, Cholongitas E, Anastasopoulou A, Diamantopoulos P, Haanen J, Gogas H. Reconsidering the management of patients with cancer with viral hepatitis in the era of immunotherapy. J Immunother Cancer 2020;8:e000943. [PMID: 33067316 DOI: 10.1136/jitc-2020-000943] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 4.5] [Reference Citation Analysis]
3 Spera AM. Safety of direct acting antiviral treatment for hepatitis C in oncologic setting: A clinical experience and a literature review. World J Hepatol 2022; 14(3): 525-534 [DOI: 10.4254/wjh.v14.i3.525] [Reference Citation Analysis]